Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
AssigneeModernaTX, Inc.
InventorsJoshua Frederick, Ailin Bai, Vladimir Presnyak, Stephen Hoge, Kerry Benenato, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Susannah Hewitt
Life of this patent
Estimating the term…
Abstract
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
Claims20
A method for treating cancer in a subject by activating T cells in vivo, comprising administering to the subject
- (i) a first messenger RNA (mRNA) comprising an open reading frame (ORF) encoding a human IL-23 polypeptide;
- (ii) a second mRNA comprising an ORF encoding a human IL-36gamma polypeptide;
- and
- (iii) a third mRNA comprising an ORF encoding a human OX40L polypeptide, thereby activating T cells in vivo to treat cancer in the subject.
A method for treating cancer in a subject by activating T cells in vivo, comprising administering to the subject
- (i) a first mRNA encoding a human IL-23 polypeptide, wherein the first mRNA comprises an ORF comprising a nucleotide sequence at least 90% identical to the nucleotide sequence as set forth in SEQ ID NO:
- 141 or comprises the nucleotide sequence as set forth in SEQ ID NO:
- 141;
- (ii) a second mRNA encoding a human IL-36gamma polypeptide, wherein the second mRNA comprises an ORF comprising a nucleotide sequence at least 90% identical to the nucleotide sequence as set forth in SEQ ID NO:
- 143 or comprises the nucleotide sequence as set forth in SEQ ID NO:
- 143;
- and
- (iii) a third mRNA encoding a human OX40L polypeptide, wherein the third mRNA comprises an ORF comprising a nucleotide sequence at least 90% identical to the nucleotide sequence as set forth in SEQ ID NO:
- 145, or comprises the nucleotide sequence as set forth in SEQ ID NO:
- 145,
- thereby activating T cells in vivo to treat cancer in the subject.
A method for treating cancer in a subject by activating T cells in vivo, comprising administering to the subject
- (i) a first mRNA encoding a human IL-23 polypeptide, wherein the first mRNA comprises a nucleotide sequence at least 90% identical to the nucleotide sequence set forth in SEQ ID NO:
- 142 or comprises the nucleotide sequence set forth in SEQ ID NO:
- 142;
- (ii) a second mRNA encoding a human IL-36gamma polypeptide, wherein the second mRNA comprises a nucleotide sequence at least 90% identical to the nucleotide sequence set forth in SEQ ID NO:
- 144 or comprises the nucleotide sequence set forth in SEQ ID NO:
- 144;
- and
- (iii) a third mRNA encoding a human OX40L polypeptide, wherein the third mRNA comprises a nucleotide sequence at least 90% identical to the nucleotide sequence set forth in SEQ ID NO:
- 146 or comprises the nucleotide sequence set forth in SEQ ID NO:
- 146,
- thereby activating T cells in vivo to treat cancer in the subject.
Dependencies are inferred from the claim text.